“We’re getting less and less referrals, and that number is dropping,” Anthony Mitarotondo, MD, director of Stony Brook Radiology, said during a recent public hearing. 

Telix Pharmaceuticals recently submitted its license application to the FDA for the investigational positron emission tomography agent TLX250-CDx (Zircaix). 
 

Images from the world's largest radiology conference include new technologies and the latest advances in MRI, CT, nuclear medicine, X-ray, artificial intelligence, and PACS/enterprise imaging.

The Biograph Vision.X is able to deliver an estimated 20% performance improvement, bolstering throughput while reducing radiotracer costs. 

Nucleus RadioPharma will use the money to establish manufacturing facilities—with one located in Rochester, Minnesota, near Mayo—and build new technology for distribution.

Robert Hendel, MD, discussed everything from declining reimbursements in cardiology to prior authorization policies in an exclusive new interview. 

Eliminating the previous “coverage with evidence development” requirement allows local MACs to dictate payment for such exams. 

The new radiotracer flurpiridaz is poised to make a major impact on nuclear cardiology. Timothy Bateman, MD, co-director of the cardiovascular radiologic imaging program at Saint Luke's Mid America Heart Institute, shared details on the tracer in a new interview.